Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth
暂无分享,去创建一个
Yukihiko Sugimoto | Shuh Narumiya | Takayuki Maruyama | Masami Narita | Izumi Hayashi | S. Narumiya | S. Yamashina | Y. Sugimoto | M. Majima | T. Maruyama | Michiyoshi Kobayashi | H. Endo | I. Hayashi | H. Kitasato | Shohei Yamashina | Takahiko Murata | H. Yoshimura | Masataka Majima | Hideki Amano | Hirahito Endo | Hidero Kitasato | Michiyoshi Kobayashi | Kazutoyo Satoh | Hirokuni Yoshimura | T. Murata | H. Amano | M. Narita | K. Satoh
[1] B. Curry,et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.
[2] M. Itoman,et al. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. , 2002, Biochemical and biophysical research communications.
[3] S. Narumiya,et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. , 2002, The Journal of clinical investigation.
[4] Rakesh K Jain,et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.
[5] S. Narumiya,et al. Cyclooxygenase 2- and prostaglandin E2 receptor EP2-dependent angiogenesis in ApcΔ716 mouse intestinal polyps , 2002 .
[6] S. Yamashina,et al. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. , 2001, Japanese journal of pharmacology.
[7] S. Narumiya,et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice , 2001, Nature Medicine.
[8] J. Marx. Anti-Inflammatories Inhibit Cancer Growth--But How? , 2001, Science.
[9] J. Pevsner,et al. Induction of vascular endothelial growth factor in human astrocytes by lead. Involvement of a protein kinase C/activator protein-1 complex-dependent and hypoxia-inducible factor 1-independent signaling pathway. , 2000, The Journal of biological chemistry.
[10] S. Dey,et al. Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.
[11] S. Yamashina,et al. Cyclo‐oxygenase‐2 enhances basic fibroblast growth factor‐induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants , 2000, British journal of pharmacology.
[12] A. Kato,et al. Colorectal cancer and non-steroidal anti-inflammatory drugs. , 2000, Acta pharmacologica Sinica.
[13] S. Narumiya,et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. , 2000, Endocrinology.
[14] S. Narumiya,et al. Prostaglandin D2 as a mediator of allergic asthma. , 2000, Science.
[15] R. DuBois,et al. The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.
[16] Y. Sasaki,et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[17] S. Narumiya,et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. , 1999, Cancer research.
[18] K. Seibert,et al. COX‐2 Inhibitors: A New Class of Antiangiogenic Agents , 1999, Annals of the New York Academy of Sciences.
[19] C. Compton,et al. Tumor–host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor β1 , 1999, Nature Medicine.
[20] J. Morrow,et al. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. , 1999, Cancer research.
[21] S. Narumiya,et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[22] C. Hawkey,et al. COX-2 inhibitors , 1999, The Lancet.
[23] S. Narumiya,et al. Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.
[24] M. Matsushita,et al. Profile of JTE-522 as a human cyclooxygenase-2 inhibitor. , 1998, Japanese journal of pharmacology.
[25] C. Koboldt,et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] Atsushi Ichikawa,et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3 , 1998, Nature.
[27] R. DuBois,et al. Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.
[28] S. Narumiya,et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. , 1998, Biochemical and biophysical research communications.
[29] N. Voelkel,et al. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. , 1997, American journal of respiratory cell and molecular biology.
[30] B. Rigas,et al. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. , 1997, Gastroenterology.
[31] R K Jain,et al. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. , 1997, The American journal of pathology.
[32] S. Narumiya,et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.
[33] S. Narumiya,et al. Failure of parturition in mice lacking the prostaglandin F receptor. , 1997, Science.
[34] R. DuBois,et al. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[35] Bruno C. Hancock,et al. Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.
[36] Raymond L. White,et al. Self-Promotion? Intimate Connections Between APC and Prostaglandin H Synthase-2 , 1996, Cell.
[37] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[38] R. DuBois,et al. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.
[39] G. Sempowski,et al. Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. , 1995, The Journal of clinical endocrinology and metabolism.
[40] S. Rodan,et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. , 1994, The Journal of clinical investigation.
[41] S. Narumiya,et al. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity , 1993, Nature.
[42] Y. Sugimoto,et al. Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins. , 1993, The Journal of biological chemistry.
[43] E. Spisni,et al. Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors. , 1992, Prostaglandins, leukotrienes, and essential fatty acids.
[44] M. Stephenson,et al. Heterogeneity in hormone responses and patterns of collagen synthesis in cloned dermal fibroblasts. , 1990, The Journal of clinical investigation.
[45] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[46] P. Gullino,et al. Role of prostaglandin E1 and copper in angiogenesis. , 1982, Journal of the National Cancer Institute.
[47] R. Page,et al. Fibroblast heterogeneity and prostaglandin regulation of subpopulations. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[49] S. Narumiya,et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. , 2002, Cancer research.
[50] S. Narumiya,et al. Adaptive cytoprotection mediated by prostaglandin I(2) is attributable to sensitization of CRGP-containing sensory nerves. , 2001, Gastroenterology.
[51] J. Marx. Cancer research. Anti-inflammatories inhibit cancer growth--but how? , 2001, Science.
[52] G. Duigou,et al. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways , 2001, Oncogene.
[53] M. Majima,et al. Chymase as a Proangiogenic Factor A POSSIBLE INVOLVEMENT OF CHYMASE-ANGIOTENSIN-DEPENDENT PATHWAY IN THE HAMSTER SPONGE ANGIOGENESIS MODEL* , 2000 .
[54] 須澤 徹夫. The role of prostaglandin E receptor Subtypes(EP1,EP2,EP3 and EP4)in bone resorption : An analysis using Specific agonists for the Respective EPs , 2000 .
[55] S. Yamamoto,et al. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. , 1997, Japanese journal of pharmacology.
[56] R. DuBois,et al. Colorectal cancer and nonsteroidal anti-inflammatory drugs. , 1997, Advances in pharmacology.
[57] S. Higuchi,et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. , 1993, General pharmacology.